Cancer increases risk of in-hospital death from COVID-19 in persons

Abstract:

:The impact of cancer on outcome of persons with coronavirus disease 2019 (COVID-19) after infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is controversial. We studied 1859 subjects with COVID-19 from seven centers in Wuhan, China, 65 of whom had cancer. We found having cancer was an independent risk factor for in-hospital death from COVID-19 in persons <65 years (hazard ratio [HR] = 2.45, 95% confidence interval [CI], 1.04, 5.76; P = 0.041) but not in those ≥65 years (HR = 1.12 [0.56, 2.24]; P = 0.740). It was also more common in those not in complete remission. Risks of in-hospital death were similar in subjects with solid cancers and those with hematological cancers. These data may help predict outcomes of persons with cancer and COVID-19.

journal_name

Leukemia

journal_title

Leukemia

authors

Li Q,Chen L,Li Q,He W,Yu J,Chen L,Cao Y,Chen W,Di Wu,Dong F,Cai L,Ran Q,Li L,Liu Q,Ren W,Gao F,Wang H,Chen Z,Gale RP,Hu Y

doi

10.1038/s41375-020-0986-7

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

2384-2391

issue

9

eissn

0887-6924

issn

1476-5551

pii

10.1038/s41375-020-0986-7

journal_volume

34

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.

    abstract::Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly conserved long non-coding RNA (lncRNA). Overexpression of MALAT1 has been demonstrated to related to poor prognosis of multiple myeloma (MM) patients. Here, we demonstrated that MALAT1 plays important roles in MM DNA repair and cell death. We ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0104-2

    authors: Hu Y,Lin J,Fang H,Fang J,Li C,Chen W,Liu S,Ondrejka S,Gong Z,Reu F,Maciejewski J,Yi Q,Zhao JJ

    更新日期:2018-10-01 00:00:00

  • Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986.

    abstract::This report documents the follow-up information on 69 hairy cell leukemia (HCL) patients treated with interferon alpha-2b (IFN) as primary treatment from 1983-86. Follow-up through October 1991 shows only 11 patients have died. Forty-one of the 57 patients completing the intended 12 or more months of initial IFN treat...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Golomb HM,Ratain MJ,Mick R,Daly K

    更新日期:1992-11-01 00:00:00

  • Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) stu

    abstract::Reliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response. However, there has been no consistent approach to JAK2-V617F detection, with assays varying markedly in performance, af...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2013.219

    authors: Jovanovic JV,Ivey A,Vannucchi AM,Lippert E,Oppliger Leibundgut E,Cassinat B,Pallisgaard N,Maroc N,Hermouet S,Nickless G,Guglielmelli P,van der Reijden BA,Jansen JH,Alpermann T,Schnittger S,Bench A,Tobal K,Wilkins B,Cu

    更新日期:2013-10-01 00:00:00

  • P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia.

    abstract::In order to further define the role of the MDR1 gene in acute myeloid leukemia (AML), we determined the association between the presence of P-glycoprotein on leukemic cells and the efficacy of therapy in patients with AML. Immunocytochemistry with monoclonal antibody C219 was performed to demonstrate the presence of P...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Zöchbauer S,Gsur A,Brunner R,Kyrle PA,Lechner K,Pirker R

    更新日期:1994-06-01 00:00:00

  • Isolation and characterization of c-fos-expressing murine bone marrow stromal cell lines supporting myeloid differentiation.

    abstract::We have previously reported that constitutive expression of c-fos oncogene allows long-term proliferation of primary mouse bone marrow stromal cells favoring the granulocytic differentiation of myeloid precursors in an in vitro assay. Retrovirus-mediated gene transfer of the human c-fos gene was used here for immortal...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Steff AM,Bouaboula M,Mouchiroud G,Arnaud S,Roux P,Cassellas P,Piechaczyk M

    更新日期:1996-03-01 00:00:00

  • Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

    abstract::c-MYC (hereafter MYC) overexpression has been recognized in aggressive B-cell lymphomas and linked to adverse prognosis. MYC activation results in widespread repression of micro-RNA (miRNA) expression and associated with lymphoma aggressive progression. Our recent study identified a MYC-miRNA-EZH2 feed-forward loop li...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.94

    authors: Zhao X,Lwin T,Zhang X,Huang A,Wang J,Marquez VE,Chen-Kiang S,Dalton WS,Sotomayor E,Tao J

    更新日期:2013-12-01 00:00:00

  • Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.

    abstract::Previous studies in pediatric patients with acute myelogenous leukemia (AML) have suggested that 2-chlorodeoxyadenosine (2CdA) is an effective therapeutic agent. Santana et al (J Clin Oncol 1992; 10: 364-370) reported a CR rate of 8/17 (95% Cl 23-72%) in children with relapsed AML and a median first CR of 21 months. T...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kornblau SM,Gandhi V,Andreeff HM,Beran M,Kantarjian HM,Koller CA,O'Brien S,Plunkett W,Estey E

    更新日期:1996-10-01 00:00:00

  • Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution.

    abstract::The study of intraclonal diversification (ID) in immunoglobulin (IG) genes offers valuable insight into the role of ongoing interactions with antigen in lymphomagenesis. We recently showed that ID in the IG heavy chain genes of patients with chronic lymphocytic leukemia (CLL) was generally limited; however, intense ID...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2010.90

    authors: Kostareli E,Sutton LA,Hadzidimitriou A,Darzentas N,Kouvatsi A,Tsaftaris A,Anagnostopoulos A,Rosenquist R,Stamatopoulos K

    更新日期:2010-07-01 00:00:00

  • Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes.

    abstract::The MDM2 gene is a gene whose product binds to p53 and regulates its function. Amplification of MDM2 has been found in human sarcomas, where it leads to inactivation of p53. In 64 cases of generally advanced myelodysplastic syndromes, we found no amplification or rearrangement of MDM2 gene by Southern analysis. MDM2 R...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Preudhomme C,Quesnel B,Vachee A,Lepelley P,Collyn-D'Hooghe M,Wattel E,Fenaux P

    更新日期:1993-08-01 00:00:00

  • A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients.

    abstract::A prospective, randomized double-blind study comparing the effects of irradiated and unirradiated white blood cells was conducted in 108 acute leukemia patients with life-threatening infections, refractory to antibiotics. The study demonstrated no significant improvement in 30-day survival or overall survival. Transfu...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/leu.2012.301

    authors: Freireich EJ,Lichtiger B,Mattiuzzi G,Martinez F,Reddy V,Kyle Wathen J

    更新日期:2013-04-01 00:00:00

  • Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.

    abstract::Previous studies demonstrated that triazene compounds (TZC) possess antitumor, antimetastatic and immunosuppressive activity, and induce novel antigenic properties in neoplastic cells. Moreover, TZC showed marked antitumor activity in patients with acute myelogenous leukemias (AML). In most cases leukemic blasts with ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Tentori L,Graziani G,Gilberti S,Lacal PM,Bonmassar E,D'Atri S

    更新日期:1995-11-01 00:00:00

  • Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

    abstract::The majority of chronic phase chronic myeloid leukemia (CML) patients treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate maintain durable responses to the drug. However, most patients relapse after withdrawal of imatinib and advanced stage patients often develop drug resistance. As CML is considered a ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404638

    authors: Brendel C,Scharenberg C,Dohse M,Robey RW,Bates SE,Shukla S,Ambudkar SV,Wang Y,Wennemuth G,Burchert A,Boudriot U,Neubauer A

    更新日期:2007-06-01 00:00:00

  • A novel CD10-positive erythroid cell line, RM10, established from a patient with chronic myelogenous leukemia.

    abstract::A novel erythroid cell line, RM10, was established from a long-term bone marrow culture of a patient with chronic myelogenous leukemia (CML). RM10 cells were positive for periodic acid Schiff (PAS), but negative for peroxidase and dual esterase. RM10 cells had la, pre B (CD10), myeloid (CD13, CD14, CD33) and erythroid...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Hirata J,Sato H,Takahira H,Shiokawa S,Endo T,Nishimura J,Katsuno M,Masuda S,Sasaki R,Fukumaki Y

    更新日期:1990-05-01 00:00:00

  • Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.

    abstract::Hemizygous deletions are common molecular abnormalities in cancer. In some cases, these deletions highlight chromosomal loci containing tumor suppressor genes that undergo homozygous inactivation. In other cases, hemizygous deletions cause disease by allelic insufficiency for one or more genes. As the intact allele ha...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.53

    authors: Ebert BL

    更新日期:2009-07-01 00:00:00

  • JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation.

    abstract::The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The JAK2V617F mutation is present in hematopoietic cells in a majority of patients with MPNs, but the mechanism(s) responsible for MPN stem cell expansion remain in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.114

    authors: Zhan H,Ma Y,Lin CH,Kaushansky K

    更新日期:2016-12-01 00:00:00

  • A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

    abstract::Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine has shown activity against MDS and elderly acute myeloid leukemia, b...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2017.186

    authors: Santini V,Allione B,Zini G,Gioia D,Lunghi M,Poloni A,Cilloni D,Sanna A,Masiera E,Ceccarelli M,Abdel-Wahab O,Terenzi A,Angelucci E,Finelli C,Onida F,Pelizzari A,Ferrero D,Saglio G,Figueroa M,Levis A

    更新日期:2018-02-01 00:00:00

  • Harmonization of molecular monitoring of CML therapy in Europe.

    abstract::The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR-ABL transcripts has proven to be the most sensitive method available, and has ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.168

    authors: Müller MC,Cross NC,Erben P,Schenk T,Hanfstein B,Ernst T,Hehlmann R,Branford S,Saglio G,Hochhaus A

    更新日期:2009-11-01 00:00:00

  • Ethnic and geographic diversity of chronic lymphocytic leukaemia.

    abstract::East Asians, Asian Indians and Amerindians have a five to ten-fold lower age-adjusted incidence rate (AAIR) of chronic lymphocytic leukaemia (CLL) compared with persons of predominately European descent. The data we review suggest a genetic rather than environmental basis for this discordance. All these populations ar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01057-5

    authors: Yang S,Varghese AM,Sood N,Chiattone C,Akinola NO,Huang X,Gale RP

    更新日期:2020-10-19 00:00:00

  • Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.

    abstract::An antisense oligodeoxynucleotide (ODN) complementary to the first six codons of the Bcl-2 mRNA, G3139 (oblimersen sodium; Genasense), has been shown to downregulate Bcl-2 and produce responses in a variety of malignancies including drug-resistant lymphoma. Incubation of ex vivo purified plasma cells from patients wit...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402768

    authors: van de Donk NW,Kamphuis MM,van Dijk M,Borst HP,Bloem AC,Lokhorst HM

    更新日期:2003-01-01 00:00:00

  • New structural chromosomal rearrangements in congenital leukemia.

    abstract::The karyotypic abnormalities and clinical data on three patients in whom acute leukemia was diagnosed within the first 6 months of life are presented. The four structural chromosomal rearrangements detected in the bone marrow from these patients, i.e., t(7;12)(q36;p13) and t(1;19)(q11;q11) in case 1, t(2;10;11;12)(q21...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Heim S,Békàssy AN,Garwicz S,Heldrup J,Wiebe T,Kristoffersson U,Mandahl N,Mitelman F

    更新日期:1987-01-01 00:00:00

  • JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.

    abstract::Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of targeted therapy i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.197

    authors: Lo MC,Peterson LF,Yan M,Cong X,Hickman JH,Dekelver RC,Niewerth D,Zhang DE

    更新日期:2013-12-01 00:00:00

  • Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges.

    abstract::Mesenchymal stem cells (MSCs) are known for being multi-potent. However, they also possess anticancer properties, which has prompted efforts to adapt MSCs for anticancer therapies. However, MSCs have also been widely implicated in pathways that contribute to tumor growth. Numerous studies have been conducted to adapt ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-018-0373-9

    authors: Lee MW,Ryu S,Kim DS,Lee JW,Sung KW,Koo HH,Yoo KH

    更新日期:2019-03-01 00:00:00

  • Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.

    abstract::The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype. Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL)...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403943

    authors: Meier M,den Boer ML,Hall AG,Irving JA,Passier M,Minto L,van Wering ER,Janka-Schaub GE,Pieters R

    更新日期:2005-11-01 00:00:00

  • Heterogeneity in protein patterns of cells from terminal blast crisis in chronic granulocytic leukemia: discrimination between lymphatic and myeloid lineages.

    abstract::Terminal blast crisis cells of chronic granulocytic leukemia are biochemically distinct. Triton-X-114 detergent phase lysates revealed that myeloid types express predominantly proteins of a 24 kd apparent molecular weight range, whereas lymphatic types do not express these molecules but a 55 kd protein band. These bio...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Doxiadis I,Dölken P,Schneider M,Wernet P,Grosse-Wilde H

    更新日期:1988-12-01 00:00:00

  • Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.

    abstract::Lovastatin is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the major regulatory enzyme of the mevalonate pathway. We have previously reported that lovastatin induces a significant apoptotic response in human acute myeloid leukemia (AML) cells. To identify the critical biochemic...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402196

    authors: Xia Z,Tan MM,Wong WW,Dimitroulakos J,Minden MD,Penn LZ

    更新日期:2001-09-01 00:00:00

  • Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

    abstract::p53 is frequently wild type (wt) in diffuse large B-cell lymphoma (DLBCL) associated with t(14;18)(q32;q21) that overexpresses BCL2. Nutlin-3a is a small molecule that activates the p53 pathway by disrupting p53-MDM2 interaction. We show that nutlin-3a activates p53 in DLBCL cells associated with t(14;18)(q32;q21), BC...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.28

    authors: Drakos E,Singh RR,Rassidakis GZ,Schlette E,Li J,Claret FX,Ford RJ Jr,Vega F,Medeiros LJ

    更新日期:2011-05-01 00:00:00

  • HTLV-I Tax trans-activation and cell growth signaling.

    abstract::We have cloned two genes for cell surface molecules, capable of delivering the intracellular signals, which are modulated for their expression by Tax. One is the gamma chain of the interleukin-2 (IL-2) receptor which is suggested to be critical for IL-2-dependent growth of human T-cell leukemia virus type I (HTLV-I) i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Nakamura M,Takasawa N,Ohbo K,Higashimura N,Ohtani K,Tanaka Y,Sugamura K

    更新日期:1997-04-01 00:00:00

  • A new t(2;5) translocation in a null cell type CD30 positive anaplastic large cell lymphoma case.

    abstract::Anaplastic large cell lymphoma (ALCL) expressing the CD30 antigen is an uncommon subtype of non-Hodgkin's lymphoma characterized by distinct morphological and clinical features. The recurrent chromosomal abnormality found in these tumours is a t(2;5)(p23;q35) which has been detected in a minority of these cases, predo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Wlodarska I,De Wolf-Peeters C,Michaux L,Mecucci C,Verhoef G,Cassiman JJ,Van den Berghe H

    更新日期:1995-10-01 00:00:00

  • Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.

    abstract::The current study was initiated to compare the anti-lymphoma activity and side-effects of prednimustine/mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) in patients with advanced low-grade non-Hodgkin's lymphomas in way of a prospective randomized multicenter trial. Two hundred and forty-six patie...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Unterhalt M,Herrmann R,Tiemann M,Parwaresch R,Stein H,Trümper L,Nahler M,Reuss-Borst M,Tirier C,Neubauer A,Freund M,Kreuser ED,Dietzfelbinger H,Bodenstein H,Engert A,Stauder R,Eimermacher H,Landys K,Hiddemann W

    更新日期:1996-05-01 00:00:00

  • IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.

    abstract::Cell lines of myeloid origin have been shown to express interleukin-2 receptors (IL-2R). Here, we demonstrate the expression of IL-2R alpha and IL-R beta on the CML blast cell line K562 by FACS analysis and cross-linking assay. Furthermore, we examined the effect of IL-2 on leukemic progenitor growth, employing K562 a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dilloo D,Hanenberg H,Lion T,Burdach S

    更新日期:1995-03-01 00:00:00